The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease

References

• Beeken WL, Busch HJ, Sylwester DL. Intestinal protein loss in Crohn's disease. Gastroenterology 1972; 62: 207–15
   PubMed Web of Science ®Google Scholar
• Hodges P, Gee M, Grace M, Sherbaniuk RW, Wensel RH, Thomson AB. Protein-energy intake and malnutrition in Crohn's disease. J Am Diet Assoc 1984; 84: 1460–4
   PubMedGoogle Scholar
• Kirschner BS, Klich JR, Kalman SS, deFavaro MV, Rosenberg IH. Reversal of growth retardation in Crohn's disease with therapy emphasizing oral nutritional restitution. Gastroenterology 1981; 80: 10–15
   PubMed Web of Science ®Google Scholar
• Bach LA, Rechler MM. Insulin-like growth factor binding proteins. Diabetes Rev 1995; 3: 38–61
   Google Scholar
• Juul A, Holm K, Kastrup KW, Pedersen SA, Michaelsen KF, Scheike T, et al. Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency. J Clin Endocrinol Metab 1997; 82: 2497–502
   PubMed Web of Science ®Google Scholar
• Frystyk J. Free insulin-like growth factors: measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res 2004; 14: 337–75
   PubMed Web of Science ®Google Scholar
• Fan J, Char D, Bagby GJ, Gelato MC, Lang CH. Regulation of insulin-like growth factor-I (IGF-I) and IGF-binding proteins by tumor necrosis factor. Am J Physiol 1995; 269: R1204–12
   PubMed Web of Science ®Google Scholar
• Wolf M, Bohm S, Brand M, Kreymann G. Proinflammatory cytokines interleukin 1 beta and tumor necrosis factor alpha inhibit growth hormone stimulation of insulin-like growth factor I synthesis and growth hormone receptor mRNA levels in cultured rat liver cells. Eur J Endocrinol 1996; 135: 729–37
   PubMed Web of Science ®Google Scholar
• Vespasiani GU, Caviglia R, Picardi A, Carotti S, Ribolsi M, Galati G, et al. Infliximab reverses growth hormone resistance associated with inflammatory bowel disease. Aliment Pharmacol Ther 2005; 21: 1063–71
   PubMed Web of Science ®Google Scholar
• Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut 1997; 40: 313–9
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000; 46: 176–81
   PubMed Web of Science ®Google Scholar
• Abreu MT, Geller JL, Vasiliauskas EA, Kam LY, Vora P, Martyak LA, et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J Clin Gastroenterol 2006; 40: 55–63
   PubMed Web of Science ®Google Scholar
• Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut 1997; 40: 228–33
   PubMed Web of Science ®Google Scholar
• Best WR, Becktel JM, Singleton JW, Kern F, Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439–44
   PubMed Web of Science ®Google Scholar
• Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980; 1: 514
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–9
   PubMed Web of Science ®Google Scholar
• Frystyk J, Dinesen B, Ørskov H. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Regul 1995; 5: 169–76
   PubMedGoogle Scholar
• Frystyk J, Skjærbæk C, Dinesen B, Ørskov H. Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Lett 1994; 348: 185–91
   PubMed Web of Science ®Google Scholar
• Westwood M, Gibson JM, Davies AJ, Young RJ, White A. The phosphorylation pattern of insulin-like growth factor-binding protein-1 in normal plasma is different from that in amniotic fluid and changes during pregnancy. J Clin Endocrinol Metab 1994; 79: 1735–41
   PubMed Web of Science ®Google Scholar
• Krassas GE, Pontikides N, Kaltsas T, Dumas A, Frystyk J, Chen JW, et al. Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. J Clin Endocrinol Metab 2003; 88: 132–5
   PubMed Web of Science ®Google Scholar
• Skogstrand K, Thorsen P, Nørgaard-Pedersen B, Schendel DE, Sørensen LC, Hougaard DM. Simultaneous measurement of 25 inflammatory markers and neurotrophins in neonatal dried blood spots by immunoassay with xMAP technology. Clin Chem 2005; 51: 1854–66
   PubMed Web of Science ®Google Scholar
• Grønbæk H, Thøgersen T, Frystyk J, Vilstrup H, Flyvbjerg A, Dahlerup JF. Low free and total insulin-like growth factor I (IGF-I) and IGF binding protein-3 levels in chronic inflammatory bowel disease: partial normalization during prednisolone treatment. Am J Gastroenterol 2002; 97: 673–8
   PubMed Web of Science ®Google Scholar
• Thomas AG, Holly JM, Taylor F, Miller V. Insulin like growth factor-I, insulin like growth factor binding protein-1, and insulin in childhood Crohn's disease. Gut 1993; 34: 944–7
   PubMed Web of Science ®Google Scholar
• Eivindson M, Grønbæk H, Nielsen JN, Frystyk J, Flyvbjerg A, Jørgensen L, et al. Insulin-like growth factors (IGFs) and IGF binding proteins in active Crohn's disease treated with omega-3 or omega-6 fatty acids and corticosteroids. Scand J Gastroenterol 2005; 40: 1214–21
   PubMed Web of Science ®Google Scholar
• Nørrelund H, Frystyk J, Jørgensen JO, Møller N, Christiansen JS, Ørskov H, et al. The effect of growth hormone on the insulin-like growth factor system during fasting. J Clin Endocrinol Metab 2003; 88: 3292–8
   PubMed Web of Science ®Google Scholar
• Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994; 15: 80–101
   PubMed Web of Science ®Google Scholar
• Underwood LE. Nutritional regulation of IGF-I and IGFBPs. J Pediatr Endocrinol Metab 1996; 9(Suppl 3)303–12
   PubMed Web of Science ®Google Scholar
• Bannerjee K, Camacho-Hübner C, Babinska K, Dryhurst KM, Edwards R, Savage MO, et al. Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J Pediatr Gastroenterol Nutr 2004; 38: 270–5
   PubMed Web of Science ®Google Scholar
• Eivindson, M, Grønbæk, H, Flyvbjerg, A, Frystyk, J, Zimmermann-Nielsen, E, Dahlerup, JF. The insulin-like growth factor (IGF)-system in active ulcerative colitis and Crohn's Disease: relations to disease activity and corticosteroid treatment. Growth Horm IGF Res 2006; in press.
   PubMed Web of Science ®Google Scholar
• Heszele MF, Price SR. Insulin-like growth factor I: the yin and yang of muscle atrophy. Endocrinology 2004; 145: 4803–5
   PubMed Web of Science ®Google Scholar
• Borrelli O, Bascietto C, Viola F, Bueno DM, Barbato M, Mancini V, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis 2004; 36: 342–7
   PubMedGoogle Scholar
• Briot K, Garnero P, Le Henanff A, Dougados M, Roux C. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor α treatment. Ann Rheum Dis 2005; 64: 1137–40
   PubMed Web of Science ®Google Scholar
• Allen JT, Bloor CA, Knight RA, Spiteri MA. Expression of insulin-like growth factor binding proteins in bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis. Am J Respir Cell Mol Biol 1998; 19: 250–8
   PubMed Web of Science ®Google Scholar
• Corkins MR, Gohil AD, Fitzgerald JF. The insulin-like growth factor axis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2003; 36: 228–34
   PubMed Web of Science ®Google Scholar
• Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 1993; 76: 1031–5
   PubMed Web of Science ®Google Scholar
• Helle SI, Ueland T, Ekse D, Frøland SS, Holly JM, Lønning PE, et al. The insulin-like growth factor system in human immunodeficiency virus infection: relations to immunological parameters, disease progression, and antiretroviral therapy. J Clin Endocrinol Metab 2001; 86: 227–33
   PubMed Web of Science ®Google Scholar
• Kratzsch J, Blum WF, Schenker E, Keller E. Regulation of growth hormone (GH), insulin-like growth factor (IGF)I, IGF binding proteins -1, -2, -3 and GH binding protein during progression of liver cirrhosis. Exp Clin Endocrinol Diabetes 1995; 103: 285–91
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541–9
   PubMed Web of Science ®Google Scholar
• Brynskov J, Nielsen OH, Ahnfelt-Rønne I, Bendtzen K. Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): a review. Dig Dis 1994; 12: 290–304
   PubMed Web of Science ®Google Scholar
• van Dullemen HM, Van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129–35
   PubMed Web of Science ®Google Scholar
• Reinisch W, Gasche C, Tillinger W, Wyatt J, Lichtenberger C, Willheim M, et al. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am J Gastroenterol 1999; 94: 2156–64
   PubMed Web of Science ®Google Scholar
• Cornillie F, Shealy D, D'Haens G, Geboes K, Van Assche G, Ceuppens J, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 2001; 15: 463–73
   PubMed Web of Science ®Google Scholar
• Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D, et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997; 159: 6276–82
   PubMed Web of Science ®Google Scholar
• Kirschner BS, Sutton MM. Somatomedin-C levels in growth-impaired children and adolescents with chronic inflammatory bowel disease. Gastroenterology 1986; 91: 830–6
   PubMed Web of Science ®Google Scholar
• Beattie RM, Camacho-Hübner C, Wacharasindhu S, Cotterill AM, Walker-Smith JA, Savage MO. Responsiveness of IGF-I and IGFBP-3 to therapeutic intervention in children and adolescents with Crohn's disease. Clin Endocrinol (Oxf) 1998; 49: 483–9
   PubMed Web of Science ®Google Scholar